(资料图片仅供参考)

近日， Innate Pharma 和 赛诺菲 宣布扩大合作，赛诺菲将从 Innate 公司的  ANKET

TM

TM

根据最新的许可协议， 赛诺菲 将向 Innate 支付 2640 万美元的预付款。Innate 还有资格获得总计 高达 14.3 亿美元 的临床前、临床、监管和商业里程碑付款以及未来净销售额的特许权使用费。

早在2016年，两家公司就签署了一项价值 4 亿美元的研究合作和许可协议，以开发和评估最多两种双特异性 NK 细胞接合剂。目前 赛诺菲 的研发团队正在对其进行评估。

其中一种名为 SAR443579 的药物靶向受体 CD123，目前正处于针对已逝或难治性急性髓性白血病、B 细胞急性淋巴细胞白血病和高危骨髓增生异常综合征的 I/II 期试验。 赛诺菲 还决定将另一种候选药物——一种名为 SAR445514 的 BCMA 靶向 NK 细胞接合剂，推进人体临床试验。

在周一早上发布的新闻稿中， 赛诺菲 全球肿瘤学研究负责人 Valeria Fantin 博士表示， 该公司正在继续探索“NK 细胞在癌症免疫治疗中的潜力，属于赛诺菲肿瘤学战略的关键支柱。 ”

“我们与 Innate 的关系符合我们与有前途的法国公司合作的承诺，并支持我们开发下一代 NK 细胞接合剂的多样化产品组合的雄心，与 赛诺菲 的同种异体 NK 细胞平台、刺激 NK 细胞和增强免疫力的工程淋巴因子高度协同。” Fantin 表示。

早在 2020 年， 赛诺菲 就以 3.58 亿美元的价格收购了同种异体 NK 细胞平台开发商 Kiadis Pharma ；今年 9 月，赛诺菲与 Scribe Therapeutics 签署了一项协议，将利用 Scribe Therapeutics 的 CRISPR 基因组编辑技术，使用于癌症的新型自然杀伤 (NK) 细胞疗法的基因改造。

合作，赛诺菲将从Innate公司的ANKETTM(Antibody-based NK Cell Engager Therapeutics)平台来靶向在各种实体瘤上过度表达的糖蛋白 B7H3。此外，赛诺菲还可以选择增加两个额外的ANKETTM靶点。确定候选药物后，赛诺菲将负责所有的开发、制造和商业化。"}}},"align":"","folded":false}},"Pkswd0y0mo4Ae0xxUMhc6eynnIc":{"id":"Pkswd0y0mo4Ae0xxUMhc6eynnIc","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"RCSEdakOeoQQsyxKSjUcVDrhncf":{"id":"RCSEdakOeoQQsyxKSjUcVDrhncf","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":2,"numToAttrib":{"0":["author","6980198808172969986"],"1":["bold","true"]}},"initialAttributedTexts":{"attribs":{"0":"*0+1i*0*1+b*0+z"},"text":{"0":"根据最新的许可协议，赛诺菲将向 Innate 支付 2640 万美元的预付款。Innate 还有资格获得总计高达 14.3 亿美元的临床前、临床、监管和商业里程碑付款以及未来净销售额的特许权使用费。 "}}},"align":"","folded":false}},"HgCMd8YESoEgiqxEDThc1ZWLnPf":{"id":"HgCMd8YESoEgiqxEDThc1ZWLnPf","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"MMUWdEkCkog4Mkxu2cQc2fOCnGh":{"id":"MMUWdEkCkog4Mkxu2cQc2fOCnGh","snapshot":{"type":"image","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","align":"center","image":{"token":"boxcnKA7SfPEoUPyLi4ZAj53JDU","mimeType":"image/png","size":349960,"scale":1,"width":850,"height":478,"name":"image.png"}}},"EK2qdOQISok0o0xR4iwcWK3xnrG":{"id":"EK2qdOQISok0o0xR4iwcWK3xnrG","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":1,"numToAttrib":{"0":["author","6980198808172969986"]}},"initialAttributedTexts":{"attribs":{"0":"*0+28"},"text":{"0":"早在2016年，两家公司就签署了一项价值 4 亿美元的研究合作和许可协议，以开发和评估最多两种双特异性 NK 细胞接合剂。目前赛诺菲的研发团队正在对其进行评估。"}}},"align":"","folded":false}},"L2Osd28I8owoqex8P8Cc6h1rniE":{"id":"L2Osd28I8owoqex8P8Cc6h1rniE","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"S0uEdi0SYoe2imxOdJZc5n7onPl":{"id":"S0uEdi0SYoe2imxOdJZc5n7onPl","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":2,"numToAttrib":{"0":["author","6980198808172969986"],"1":["abbreviation-data","{"id":"fc5f18db-2b6e-4ff6-85cf-5005a544c22b","abbr_ids":"enterprise_7064483356278046724","is_visible":1,"is_first":1}"]}},"initialAttributedTexts":{"attribs":{"0":"*0+27*1*0+1*0+1v"},"text":{"0":"其中一种名为 SAR443579 的药物靶向受体 CD123，目前正处于针对已逝或难治性急性髓性白血病、B 细胞急性淋巴细胞白血病和高危骨髓增生异常综合征的 I/II 期试验。赛诺菲还决定将另一种候选药物——一种名为 SAR445514 的 BCMA 靶向 NK 细胞接合剂，推进人体临床试验。"}}},"align":"left","folded":false}},"Di2edeScUoQwW4x4TSockbCWnrg":{"id":"Di2edeScUoQwW4x4TSockbCWnrg","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"EoaEdqYWAokcaexsRXUc72WZnCd":{"id":"EoaEdqYWAokcaexsRXUc72WZnCd","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":3,"numToAttrib":{"0":["author","6980198808172969986"],"1":["textHighlightBackground","rgba(255,246,122,0.8)"],"2":["bold","true"]}},"initialAttributedTexts":{"attribs":{"0":"*0+r*0*1+e*0+6*0*2+16*0+2"},"text":{"0":"在周一早上发布的新闻稿中，赛诺菲全球肿瘤学研究负责人 Valeria Fantin 博士表示，该公司正在继续探索“NK 细胞在癌症免疫治疗中的潜力，属于赛诺菲肿瘤学战略的关键支柱。”"}}},"align":"left","folded":false}},"H2OSdcIYGoSuIOx4KObchr5Tndf":{"id":"H2OSdcIYGoSuIOx4KObchr5Tndf","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"FMA0dk4SwoGAgoxO0ImcSYGBn9c":{"id":"FMA0dk4SwoGAgoxO0ImcSYGBn9c","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":1,"numToAttrib":{"0":["author","6980198808172969986"]}},"initialAttributedTexts":{"attribs":{"0":"*0+3d"},"text":{"0":"“我们与 Innate 的关系符合我们与有前途的法国公司合作的承诺，并支持我们开发下一代 NK 细胞接合剂的多样化产品组合的雄心，与赛诺菲的同种异体 NK 细胞平台、刺激 NK 细胞和增强免疫力的工程淋巴因子高度协同。” Fantin 表示。"}}},"align":"left","folded":false}},"IGo4dMEaiosGSQxykyEcYZG1ndc":{"id":"IGo4dMEaiosGSQxykyEcYZG1ndc","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"apool":{"nextNum":0,"numToAttrib":{}},"initialAttributedTexts":{"attribs":{"0":""},"text":{"0":""}}},"align":"","folded":false}},"UWyedugU6o0OWCxeR6fccwRGncb":{"id":"UWyedugU6o0OWCxeR6fccwRGncb","snapshot":{"type":"text","parent_id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","comments":[],"locked":false,"hidden":false,"author":"6980198808172969986","children":[],"text":{"initialAttributedTexts":{"text":{"0":"早在 2020 年，赛诺菲就以 3.58 亿美元的价格收购了同种异体NK 细胞平台开发商Kiadis Pharma；今年9月，赛诺菲与 Scribe Therapeutics 签署了一项协议，将利用 Scribe Therapeutics 的 CRISPR 基因组编辑技术，使用于癌症的新型自然杀伤 (NK) 细胞疗法的基因改造。"},"attribs":{"0":"*0*1+r*0+h*0*2+d*0+b*0*2+k*0*1+8*0+1x"}},"apool":{"numToAttrib":{"0":["author","6980198808172969986"],"1":["unlink","true"],"2":["textHighlightBackground","rgba(255,246,122,0.8)"]},"nextNum":3}},"align":"left","folded":false}},"ZgpPdjp3YowvBmx3FUYcyhnRn2f":{"id":"ZgpPdjp3YowvBmx3FUYcyhnRn2f","snapshot":{"type":"page","parent_id":"","comments":null,"locked":false,"hidden":false,"author":"6980198808172969986","children":["OKOOdwOe4o4O6WxYH8JcJzt1npb","SAkodYEoAo4yQexSm57cm5SZnkd","AeIedMYwgogC8cxmIYqc1en9nIb","C0AsdgGcwoaesqxaqyrcBHddnlc","V2C6dyKSooQY40xYnzIcbf5mnIc","QGEkdGmskoMQKIx6AvdcXwoXnBZ","VeqydKkW2oSGoqxElWncZGZsnmh","ZwGQdiwcKokmycxSJlkcGNZAn39","Pkswd0y0mo4Ae0xxUMhc6eynnIc","RCSEdakOeoQQsyxKSjUcVDrhncf","HgCMd8YESoEgiqxEDThc1ZWLnPf","MMUWdEkCkog4Mkxu2cQc2fOCnGh","EK2qdOQISok0o0xR4iwcWK3xnrG","L2Osd28I8owoqex8P8Cc6h1rniE","S0uEdi0SYoe2imxOdJZc5n7onPl","Di2edeScUoQwW4x4TSockbCWnrg","EoaEdqYWAokcaexsRXUc72WZnCd","H2OSdcIYGoSuIOx4KObchr5Tndf","FMA0dk4SwoGAgoxO0ImcSYGBn9c","IGo4dMEaiosGSQxykyEcYZG1ndc","UWyedugU6o0OWCxeR6fccwRGncb","PSSOdQKwWoSyGgxi0CWcpruUnqh","C4audCOUQok6cexKuAocfYFznac","FsMGdEcMQogcUmx03VpcKUIanct","GkO4dy4YMokEuAxSY6EcFs3GnIf"],"text":{"apool":{"nextNum":1,"numToAttrib":{"0":["author","6980198808172969986"]}},"initialAttributedTexts":{"attribs":{"0":"*0+w"},"text":{"0":"超14亿美元，赛诺菲深耕NK细胞领域，称属于肿瘤学战略的关键支柱"}}},"align":""}}},"payloadMap":{"VeqydKkW2oSGoqxElWncZGZsnmh":{"level":1},"ZwGQdiwcKokmycxSJlkcGNZAn39":{"level":1},"Pkswd0y0mo4Ae0xxUMhc6eynnIc":{"level":1},"RCSEdakOeoQQsyxKSjUcVDrhncf":{"level":1},"HgCMd8YESoEgiqxEDThc1ZWLnPf":{"level":1},"EK2qdOQISok0o0xR4iwcWK3xnrG":{"level":1},"L2Osd28I8owoqex8P8Cc6h1rniE":{"level":1},"S0uEdi0SYoe2imxOdJZc5n7onPl":{"level":1},"Di2edeScUoQwW4x4TSockbCWnrg":{"level":1},"EoaEdqYWAokcaexsRXUc72WZnCd":{"level":1},"H2OSdcIYGoSuIOx4KObchr5Tndf":{"level":1},"FMA0dk4SwoGAgoxO0ImcSYGBn9c":{"level":1},"IGo4dMEaiosGSQxykyEcYZG1ndc":{"level":1},"UWyedugU6o0OWCxeR6fccwRGncb":{"level":1}},"extra":{"mention_page_title":{},"external_mention_url":{}},"isKeepQuoteContainer":false,"selection":[{"id":8,"type":"text","selection":{"start":0,"end":0},"recordId":"VeqydKkW2oSGoqxElWncZGZsnmh"},{"id":9,"type":"text","selection":{"start":0,"end":174},"recordId":"ZwGQdiwcKokmycxSJlkcGNZAn39"},{"id":10,"type":"text","selection":{"start":0,"end":0},"recordId":"Pkswd0y0mo4Ae0xxUMhc6eynnIc"},{"id":11,"type":"text","selection":{"start":0,"end":100},"recordId":"RCSEdakOeoQQsyxKSjUcVDrhncf"},{"id":12,"type":"text","selection":{"start":0,"end":0},"recordId":"HgCMd8YESoEgiqxEDThc1ZWLnPf"},{"id":13,"type":"block","recordId":"MMUWdEkCkog4Mkxu2cQc2fOCnGh"},{"id":14,"type":"text","selection":{"start":0,"end":80},"recordId":"EK2qdOQISok0o0xR4iwcWK3xnrG"},{"id":15,"type":"text","selection":{"start":0,"end":0},"recordId":"L2Osd28I8owoqex8P8Cc6h1rniE"},{"id":16,"type":"text","selection":{"start":0,"end":147},"recordId":"S0uEdi0SYoe2imxOdJZc5n7onPl"},{"id":17,"type":"text","selection":{"start":0,"end":0},"recordId":"Di2edeScUoQwW4x4TSockbCWnrg"},{"id":18,"type":"text","selection":{"start":0,"end":91},"recordId":"EoaEdqYWAokcaexsRXUc72WZnCd"},{"id":19,"type":"text","selection":{"start":0,"end":0},"recordId":"H2OSdcIYGoSuIOx4KObchr5Tndf"},{"id":20,"type":"text","selection":{"start":0,"end":121},"recordId":"FMA0dk4SwoGAgoxO0ImcSYGBn9c"},{"id":21,"type":"text","selection":{"start":0,"end":0},"recordId":"IGo4dMEaiosGSQxykyEcYZG1ndc"},{"id":22,"type":"text","selection":{"start":0,"end":165},"recordId":"UWyedugU6o0OWCxeR6fccwRGncb"}],"pasteFlag":"153d3a9a-4edb-4981-a125-03a119eb4c9a"}" data-lark-record-format="docx/record">